Spasticity

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence

Saturday, May 23, 2020 - 6:00am

The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.

Key Points: 
  • The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.
  • Symptom recurrence significantly impacted patients quality of life, including sleep, relationships, performance of daily tasks and working lives.
  • Eligible participants were over 18 years old and had (or cared for someone with) spasticity or cervical dystonia (CD) treated with BoNT-A for at least one year.
  • How do patients with cervical dystonia (CD) experience their botulinum neurotoxin type a (BoNT-A) treatment cycle: results from an international online survey.

Medtronic Launches Efficio™ Software to Help Clinicians Efficiently Manage Targeted Drug Delivery Therapy with SynchroMed™ II

Thursday, January 23, 2020 - 1:30pm

DUBLIN, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the launch ofEfficio, a cloud-based data management software for use with the SynchroMed II intrathecal drug delivery system, that will allow clinicians to more efficiently manage their targeted drug delivery pump practices to treat patients with chronic pain, cancer pain and severe spasticity.

Key Points: 
  • DUBLIN, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced the launch ofEfficio, a cloud-based data management software for use with the SynchroMed II intrathecal drug delivery system, that will allow clinicians to more efficiently manage their targeted drug delivery pump practices to treat patients with chronic pain, cancer pain and severe spasticity.
  • Efficio also helps me manage pump refill dates, pump replacements, and monitor trends in dosing and patient function.
  • Efficio marks another step in our journey to simplify targeted drug delivery therapy, said Charlie Covert, vice president and general manager of the Targeted Drug Delivery business, which is part of the Restorative Therapies Group at Medtronic.
  • The SynchroMed II intrathecal drug delivery system offers a safe, proven, and effective way to manage chronic pain, cancer pain and severe spasticity for appropriate patients.

Ipsen: Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy

Monday, January 6, 2020 - 6:00am

Having a therapeutic option approved for both upper and lower limb indications creates a real benefit for the patient as it allows a holistic treatment approach for any patients with multi-focal spasticity.

Key Points: 
  • Having a therapeutic option approved for both upper and lower limb indications creates a real benefit for the patient as it allows a holistic treatment approach for any patients with multi-focal spasticity.
  • As of 31 December 2018, Dysport had marketing authorization in more than 85 countries for therapeutic treatment indications and more than 30 years of clinical experience.
  • For the treatment of focal spasticity, Dysport can also be administered by healthcare professionals having received appropriate training and qualification in accordance with national guidelines (e.g.
  • The group develops and commercializes innovative medicines in three key therapeutic areas Oncology, Neuroscience and Rare Diseases.

Catalent to Partner with Ethicann on New Fast-Dissolve Cannabinoid-Based Treatment for Multiple Sclerosis Spasticity

Tuesday, December 3, 2019 - 2:00pm

One of the more common symptoms of MS, muscular spasticity causes feelings of stiffness and a wide range of involuntary muscle spasms in patients.

Key Points: 
  • One of the more common symptoms of MS, muscular spasticity causes feelings of stiffness and a wide range of involuntary muscle spasms in patients.
  • Ethicann will investigate the new Zydis product for the treatment of patients who have shown inadequate response to other symptomatic treatments or who have difficulty tolerating the side effects of other treatments.
  • Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.
  • Ethicann Pharmaceuticals develops cannabinoid-based ethical pharmaceuticals for treatment of a variety of disorders.

FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy

Thursday, October 24, 2019 - 12:30pm

This marks the 11th BOTOX therapeutic indication,having been approved for pediatric upper limb spasticity (ULS) earlier this year.

Key Points: 
  • This marks the 11th BOTOX therapeutic indication,having been approved for pediatric upper limb spasticity (ULS) earlier this year.
  • The FDA approval is based on a Phase 3 study evaluating the safety and efficacy of BOTOX in more than 300 pediatric patients aged two to 17 years old being treated for lower limb spasticity.
  • While trial participants had cerebral palsy, the approved indication excludes lower limb spasticity caused by cerebral palsy due to marketing exclusivity by another company.
  • In pediatric patients treated with BOTOX for lower limb spasticity, upper respiratory tract infection was not reported with an incidence greater than placebo.

Growth of Spasticity Treatment Market to Be Impacted by Advent of Neurostimulation Devices | Technavio

Friday, October 18, 2019 - 9:00pm

Spasticity Treatment Market Landscape 2019-2023: Geographic landscape

Key Points: 
  • Spasticity Treatment Market Landscape 2019-2023: Geographic landscape
    Spasticity Treatment Market Landscape 2019-2023: Type
    Register for a free trial today and gain instant access to 10,000+ market research reports.
  • Oral medication and physical therapy or intravenous therapy are proved to be ineffective in many patients.
  • This is encouraging companies to develop novel drug delivery systems that improves treatment efficacy by delivering drugs to the target site.
  • As a result, vendors are developing devices such as neurostimulation devices, which are used in combination with the available medications.

Neurana Pharmaceuticals to Participate in Solebury Trout Private Company Showcase

Tuesday, October 15, 2019 - 1:28pm

SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson, president and chief executive officer, will present at the Solebury Trout Private Company Showcase, on Friday, October 18 at 10:20 a.m. Eastern Time at Davis Polk & Wardwell, LLP in New York.

Key Points: 
  • SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson, president and chief executive officer, will present at the Solebury Trout Private Company Showcase, on Friday, October 18 at 10:20 a.m. Eastern Time at Davis Polk & Wardwell, LLP in New York.
  • Neurana Pharmaceuticals, Inc. is a privately held biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, such as acute, painful muscle spasms of the neck and back and spasticity.
  • For additional information please visit www.neuranapharma.com .

Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy

Thursday, September 26, 2019 - 1:15pm

We believe the data for both pediatric upper and lower limb spasticity underscore the role of Dysportas an important treatment option for patients seeking long-lasting spasticity symptom relief.

Key Points: 
  • We believe the data for both pediatric upper and lower limb spasticity underscore the role of Dysportas an important treatment option for patients seeking long-lasting spasticity symptom relief.
  • Treatment with Dysport and other botulinum toxin products can result in swallowing or breathing difficulties.
  • Adults with lower limb spasticity (5%): falls, muscular weakness, and pain in extremity and with upper limb spasticity (4%): muscular weakness.
  • Pediatric patients with lower limb spasticity (10%): nasopharyngitis, cough and pyrexia and with upper limb spasticity (10%): upper respiratory tract infection and pharyngitis.

Osmotica Pharmaceuticals plc to Present at 2019 Wells Fargo Healthcare Conference

Wednesday, August 28, 2019 - 9:30pm

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.osmotica.com under the Investor & News section.

Key Points: 
  • The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.osmotica.com under the Investor & News section.
  • Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
  • Osmotica has a latestage development pipeline highlighted by two NDA candidates that recently completed PhaseIII clinical trials: arbaclofen ER for spasticity in multiple sclerosis patients and RVL1201 for the treatment of acquired blepharoptosis, or droopy eyelid.
  • Osmotica has operations in the United States, Argentina, and Hungary.

FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity

Friday, June 21, 2019 - 12:30pm

The FDA is also reviewing an additional sBLA for the use of BOTOX to treat pediatric patients with lower limb spasticity, with a decision expected in the fourth quarter of this year.

Key Points: 
  • The FDA is also reviewing an additional sBLA for the use of BOTOX to treat pediatric patients with lower limb spasticity, with a decision expected in the fourth quarter of this year.
  • We also look forward to the FDA's decision on pediatric lower limb spasticity and continuing to serve our patients globally."
  • The FDA approval is based on data from two Phase 3 studies evaluating the safety and efficacy of BOTOX in over 200 pediatric patients with upper limb spasticity.
  • In pediatric patients treated with BOTOX for upper limb spasticity, upper respiratory tract infections were reported more frequently.